Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Johnson & Johnson has received three separate subpoenas from the US attorney's offices in Philadelphia, Boston and San Francisco, relating to marketing practices.
Subscribe to our email newsletter
The subpoenas relate to investigations into the sales and marketing of Risperdal by Janssen, Topamax by Ortho-McNeil and Natrecor by Scios – each subsidiaries of Johnson & Johnson. The subpoenas request information regarding Johnson & Johnson’s corporate supervision and oversight of these three subsidiaries.
The investigations, which J&J has previously disclosed, relates to allegations of “off-label marketing” – the practice of marketing drugs for indications which have not been approved. Although physicians are free to prescribe any approved drug if they believe it will help a patient, drug companies are prohibited from marketing drugs in unapproved indications.
Risperdal is approved for schizophrenia, Topamax is an anti-seizure drug and Natrecor is for congestive heart failure patients. Johnson & Johnson said that it will cooperate in responding to these requests.